To be eligible, patients must undergo a full neuropsychological panel to inspect for MCI or the mild dementia stage of AD with confirmed Aβ pathology on amyloid/tau PET scan or other cerebrospinal fluid AD biomarkers, such as elevated P-tau or Aβ42 [129]. Here, MAPT is linked to dementia.